Matt Gline (L) and Vivek Ramaswamy
January 25, 2021 09:30 AM ESTUpdated 01:19 PM
Bioregnum
Opinion

Scoop: Vivek Ra­maswamy is hand­ing the CEO job to a top lieu­tenant at Roivant — but he’s not ex­act­ly leav­ing the biotech scene

Over the past 7 years since found­ing Roivant, Vivek Ra­maswamy has been a con­stant blur of biotech build­ing mo­tion.

He launched his first biotech with …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times